GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update
by Renee Jackson · The Cerbat GemGeoVax Labs Inc. (NASDAQ:GOVX – Get Free Report) saw a significant decrease in short interest in December. As of December 31st, there was short interest totaling 1,514,630 shares, a decrease of 51.5% from the December 15th total of 3,124,146 shares. Approximately 5.1% of the shares of the stock are short sold. Based on an average daily volume of 6,248,406 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily volume of 6,248,406 shares, the days-to-cover ratio is currently 0.2 days. Approximately 5.1% of the shares of the stock are short sold.
GeoVax Labs Price Performance
GOVX traded down $0.55 during trading hours on Wednesday, reaching $2.93. The company’s stock had a trading volume of 244,817 shares, compared to its average volume of 196,373. The stock has a market cap of $3.52 million, a PE ratio of -0.08 and a beta of 3.67. GeoVax Labs has a fifty-two week low of $2.87 and a fifty-two week high of $57.88. The business’s 50-day moving average is $8.09 and its 200-day moving average is $13.60.
GeoVax Labs (NASDAQ:GOVX – Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($7.75) EPS for the quarter, missing analysts’ consensus estimates of ($6.00) by ($1.75). GeoVax Labs had a negative net margin of 403.88% and a negative return on equity of 489.67%. Analysts expect that GeoVax Labs will post -4.49 EPS for the current year.
Wall Street Analysts Forecast Growth
GOVX has been the subject of several research analyst reports. D. Boral Capital reduced their target price on GeoVax Labs from $225.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, November 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $187.50.
Get Our Latest Analysis on GeoVax Labs
Institutional Investors Weigh In On GeoVax Labs
A number of institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new stake in shares of GeoVax Labs in the 1st quarter valued at approximately $27,000. Hudson Bay Capital Management LP acquired a new stake in GeoVax Labs in the 3rd quarter valued at approximately $47,000. Armistice Capital LLC acquired a new stake in GeoVax Labs in the 3rd quarter valued at approximately $253,000. Finally, Sabby Management LLC purchased a new stake in GeoVax Labs in the third quarter valued at approximately $313,000. 6.09% of the stock is currently owned by institutional investors and hedge funds.
About GeoVax Labs
GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.
The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.